Dr. Slassi was the Founder, President and Chief Scientific Officer of Fluorinov Pharma Inc. acquired by Trillium in January 2016. With over 25 years of experience in the successful identification of small molecule drug candidates across multiple therapeutic areas including oncology, neurology and gastro-intestinal, Dr. Slassi has advanced over 16 drug candidates into late-stage preclinical and clinical development. Prior to founding Fluorinov, Dr. Slassi held high level positions at NPS Pharmaceuticals, Cascade Therapeutics, Allelix Biopharmaceuticals and Inc., Boehringer Ingelheim Research Inc.. Presently, Dr. Slassi holds a position of Senior Vice President, Discovery Research at Trillium Therapeutics Inc. He is an inventor with over 120 issued and published patents and patent applications, and author of more than 65 scientific and review articles published in international peer reviewed journals. Dr. Slassi holds a Ph.D. in chemistry from the University of Claude Bernard, Lyon, France and completed his postdoctoral work in the Chemistry Department at the University of Montreal, Canada.